Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer

Abstract Background Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression...

Full description

Bibliographic Details
Main Authors: Minjiang Chen, Yan Xu, Jing Zhao, Ji Li, Xiangning Liu, Wei Zhong, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Thoracic Cancer
Subjects:
Core needle biopsy
EBB
EBUS‐TBNA
immune checkpoint inhibitor
PD‐L1 expression
Online Access:https://doi.org/10.1111/1759-7714.14075

Internet

https://doi.org/10.1111/1759-7714.14075

Similar Items